Biotech · Private company
Merz Pharmaceuticals GmbH
Track this companyFree. Adds Merz Pharmaceuticals GmbH to your Dealase workspace and tells you when its record changes.
Clinical trials113 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- IncobotulinumtoxinA (2 Units per kg body weight)Phase 3 · Cerebral PalsyClinicalTrials.gov · fetched Nov 12, 2026
- IncobotulinumtoxinA (6 Units per kg body weight)Phase 3 · Cerebral PalsyClinicalTrials.gov · fetched Nov 12, 2026
- IncobotulinumtoxinA (8 Units per kg body weight)Phase 3 · Cerebral PalsyClinicalTrials.gov · fetched Nov 12, 2026
- IncobotulinumtoxinA (Xeomin) (20 units)Phase 3 · Glabellar LinesClinicalTrials.gov · fetched Nov 12, 2026
- NT 201Phase 3 · Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain InjuryClinicalTrials.gov · fetched Nov 12, 2026
- IncobotulinumtoxinAPhase 2 · Essential Tremor of the Upper LimbsClinicalTrials.gov · fetched Nov 12, 2026
- NT 201Phase 2 · Essential Tremor of the Upper LimbClinicalTrials.gov · fetched Nov 12, 2026
- No intervention- only one time surveyBlepharospasmClinicalTrials.gov · fetched Nov 12, 2026
- Xeomin®Cervical DystoniaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials11
- IncobotulinumtoxinA for Provoked Vestibulodynia With Overactive Pelvic Floor Muscle DysfunctionPHASE2 · RECRUITING · started Feb 27, 2026ClinicalTrials.gov NCT07486830 · fetched Nov 12, 2026
- Xeomin® and Gait Related Mobility After StrokePHASE4 · RECRUITING · started Oct 19, 2021ClinicalTrials.gov NCT04908423 · fetched Nov 12, 2026
- A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the ArmPHASE2 · COMPLETED · started Feb 24, 2021ClinicalTrials.gov NCT04766723 · fetched Nov 12, 2026
- Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial LinesPHASE3 · COMPLETED · started Sep 23, 2020ClinicalTrials.gov NCT04594213 · fetched Nov 12, 2026
- Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain InjuryPHASE3 · ACTIVE_NOT_RECRUITING · started Sep 16, 2019ClinicalTrials.gov NCT03992404 · fetched Nov 12, 2026
- Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown LinesPHASE2 · COMPLETED · started Jan 23, 2019ClinicalTrials.gov NCT03806933 · fetched Nov 12, 2026
- Botulinum Toxin A to Treat Arm TremorPHASE2 · COMPLETED · started Dec 5, 2014ClinicalTrials.gov NCT02207946 · fetched Nov 12, 2026
- Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral PalsyPHASE3 · COMPLETED · started Mar 28, 2014ClinicalTrials.gov NCT02002884 · fetched Nov 12, 2026
- Blepharospasm Patient Survey for Patients With BlepharospasmCOMPLETED · started Sep 1, 2012ClinicalTrials.gov NCT01686061 · fetched Nov 12, 2026
- Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia FlexPHASE4 · COMPLETED · started Jan 20, 2012ClinicalTrials.gov NCT01486264 · fetched Nov 12, 2026
- Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown LinesPHASE3 · COMPLETED · started Jun 18, 2007ClinicalTrials.gov NCT00512135 · fetched Nov 12, 2026